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Abstract Aphasia has a large impact on the quality of life
and adds significantly to the costs of stroke care. Early
recognition of aphasia in stroke patients is important for
prognostication and well-timed treatment planning. We
aimed to identify available screening tests for differenti-
ating between aphasic and non-aphasic stroke patients, and
to evaluate test accuracy, reliability, and feasibility. We
searched PubMed, EMbase, Web of Science, and Psy-
cINFO for published studies on screening tests aimed at
assessing aphasia in stroke patients. The reference lists of
the selected articles were scanned, and several experts were
contacted to detect additional references. Of each screening
test, we estimated the sensitivity, specificity, likelihood
ratio of a positive test, likelihood ratio of a negative test,
and diagnostic odds ratio (DOR), and rated the degree of
bias of the validation method. We included ten studies
evaluating eight screening tests. There was a large varia-
tion across studies regarding sample size, patient charac-
teristics, and reference tests used for validation. Many
papers failed to report on the consecutiveness of patient
inclusion, time between aphasia onset and administration
of the screening test, and blinding. Of the three studies that
were rated as having an intermediate or low risk of bias, the
DOR was highest for the Language Screening Test and
ScreeLing. Several screening tools for aphasia in stroke are
available, but many tests have not been verified properly.
Methodologically sound validation studies of aphasia
screening tests are needed to determine their usefulness in
clinical practice.
Keywords Cerebrovascular disease/stroke  Infarction 
Intracerebral hemorrhage  Diagnostic test assessment 
Aphasia  Screening test
Introduction
For people aged 65 years or more, the worldwide preva-
lence of stroke ranges from 46 to 73 per 1000 persons [1].
This number is likely to increase in the coming years due to
aging of the population. Approximately 30 % of stroke
survivors have aphasia in the acute phase of stroke [2], a
condition affecting daily communication and thus quality
of life. Aphasia adds significantly to the costs of patient
care after stroke due to a longer hospital stay [3], and
patients with aphasia are more frequently discharged to a
rehabilitation center than those without [4]. The initial
severity of aphasia is an important factor determining the
prognosis of patients with aphasia due to stroke [5, 6]. It
has repeatedly been suggested that the treatment of aphasia
should be initiated as soon as possible after stroke,
although consistent evidence for a beneficial effect of early
language therapy has not been published yet [7].
Altogether, it is pivotal that the presence and severity of
aphasia are adequately evaluated in patients who suffered a
stroke. A large number of diagnostic instruments are
available to examine the type and degree of aphasia. As
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many of these diagnostic test batteries are fairly demanding
and time-consuming, they may be too cumbersome for
stroke patients in the acute phase. Given that the aphasia
characteristics are generally instable shortly after stroke
and can change rapidly, extensive testing may be a waste of
time and resources. In addition, a speech and language
therapist (SLT) is not always sufficiently available in the
first days after stroke to obtain a detailed linguistic profile.
Hence, a short and simple screening test, easy to administer
by various disciplines, is essential for referring patients for
additional assessment and adequate language therapy.
Furthermore, advice regarding communication may be
better personalized using results from screening tests.
The aim of this review was to identify available
screening tests for differentiating between aphasic and non-
aphasic patients after stroke, and to evaluate the accuracy,
reliability, and feasibility of those tests.
Methods
Search strategy
We searched PubMed, EMbase, Web of Science, and
PsycINFO for published studies on screening tests aimed at
assessing the presence and/or severity of aphasia in patients
who suffered an ischemic or hemorrhagic stroke. The fol-
lowing search string was used for NLM Pubmed-Medline
and was adapted for the other databases:
(cerebrovascular disorders[mesh:noexp] OR brain
ischemia[mesh] OR intracranial embolism and thrombo-
sis[mesh] OR intracranial hemorrhages[mesh] OR
stroke[mesh:noexp] OR vertebral artery dissection[mesh:-
noexp] OR stroke*[tw] OR poststroke*[tw] OR cva[tw]
OR cvas[tw] OR cerebrovasc*[tw] OR cerebral vasc*[tw]
OR ((cerebr*[tw] OR intracerebr*[tw] OR cerebell*[tw]
OR brain*[tw] OR vertebrobasilar*[tw] OR intracran*[tw])
AND (infarct*[tw] OR ischem*[tw] OR ischaem*[tw] OR
hemorrh*[tw] OR haemorrh*[tw] OR hematom*[tw] OR
haematom*[tw] OR thrombos*[tw] OR thrombot*[tw] OR
thromboembol*[tw] OR thrombol*[tw] OR apoplex*[tw]
OR emboli*[tw] OR bleed*[tw]))) AND (aphas*[tw] OR
logastheni*[tw] OR logagnos*[tw] OR logamnes*[tw] OR
alogi*[tw] OR anepia*[tw] OR dysphasi*[tw] OR lich-
theim*[tw]) AND (test[tw] OR tests[tw] OR testing*[tw]
OR screen*[tw] OR tool*[tw] OR instrument*[tw] OR
assessment*[tw]) AND (accura*[tw] OR sensitiv*[tw] OR
specificit*[tw] OR psychometr*[tw] OR psychometr*[tw]
OR predictive value*[tw]). We applied no search limits.
The reference lists of the selected articles were checked,
and experts in the field of aphasia research were contacted
to detect additional published studies. The initial search
was carried out in March 2012 and updated in May 2015
with search in Pubmed.
Selection of studies
Eligible for inclusion were full-text articles, written in
Dutch, English, French, German or Spanish, on cohort or
cross-sectional studies of stroke patients who underwent a
screening test to detect aphasia. A screening test was
defined as a diagnostic test designed to assess the pres-
ence and/or severity of aphasia, requiring a short turn-
around time that is at most 15 min. Studies evaluating
patients with aphasia due to other causes than stroke or
with an unspecified etiology were not included. We also
excluded studies in which test scores of aphasic stroke
patients were compared with those from healthy controls
instead of stroke patients without aphasia, as we specifi-
cally aimed to evaluate screening tests suitable for use in
clinical practice.
Articles had to report the results of the screening test for
aphasia as well as those from a reference test or gold
standard. Data should be described in such a way that the
sensitivity and specificity of the screening test could be
calculated. If sensitivity and specificity were given without
reporting the original data, the authors of the paper were
contacted. In the case, authors were not able to provide the
requested data; the study was excluded from this review.
First, titles and abstracts of the retrieved studies were
checked, and obviously, irrelevant articles were excluded.
If a decision could not be made based on the information in
the title and abstract, then the full-text article was checked
for the above-mentioned in- and exclusion criteria.
Data extraction
From the selected studies, we recorded the clinical char-
acteristics of the patient sample (age, sex, stroke type, and
number of patients with and without aphasia). The fol-
lowing features of the validation method were collected:
consecutiveness of patient inclusion, the type of reference
test that was used, and blinding of the test assessors. All
estimates of test accuracy reported in the studies had to be
based on the exact numbers of patients and were recalcu-
lated to check for errors and non-verification (that is
whether only patients who could be assessed with the
reference as well as with the screening test were included
and reported which indicates selection bias). We collected
the following data on the screening tests: the language in
which the validation study was conducted, subtests, score
range, time needed for administration, and type of patients
for which the test was initially developed, and reported
suitability for bedside use.
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Data analysis
We expressed the results of the validation studies of each
screening test in 2 9 2 tables and estimated the sensitivity,
specificity, likelihood ratio of a positive test (LR?), and
the likelihood ratio of a negative test (LR-). Sensitivity
was estimated by the number of aphasic patients who were
correctly classified with the screening test divided by the
total number of patients with aphasia. Specificity was
estimated by the number of patients without aphasia who
were correctly classified divided by the total number of
patients without aphasia. LR? was estimated by the sen-
sitivity divided by 1-specificity. LR- was estimated by
dividing 1-sensitivity by the specificity [8]. The diagnostic
odds ratio (DOR) was used as a single measure of test
accuracy and was calculated by dividing the LR? by the
LR- [9].
We evaluated the methodological quality of the selected
studies by scoring three items: consecutiveness of patient
inclusion, representativeness of the patient sample, and
blinding. Consecutive patient inclusion is essential to
eliminate selection bias and to ensure that the full range of
aphasia types and severities is represented in the patient
sample. Furthermore, the patient sample should be repre-
sentative for the general stroke population, since this is the
population in which the screening test will be used.
Blinding is of importance to minimize expectation bias.
The assessor of the screening test should not be aware of
the results of the reference test, and vice versa [8].
The score assigned for the representativeness of the
patient sample in the validation study (‘0’ not representa-
tive or not reported, ‘1’ fairly representative or partially not
reported, or ‘2’ very representative) was based on the size
of the cohort, available data on stroke type, and mean age
and sex of the patient sample. Consecutiveness was scored
as either ‘0’ (no consecutive inclusion or consecutiveness
not reported) or ‘2’ (consecutive inclusion of patients). The
degree of blinding was rated as ‘0’ (when assessment was
not blinded or blinding was not reported on), ‘1’ (in the
case of blinding for the screening test only, or blinding
without further specification), or ‘2’ (in the case of blinding
for both the reference and the screening test).
Finally,we assigned a score for the risk of bias based on the
three above-mentioned items. A total score of B2 was clas-
sified as high risk of bias, a total score of 3 or 4 as intermediate
risk of bias, and a total score of C5 as low risk of bias.
Results
The electronic search resulted in 1004 records. We iden-
tified 13 additional articles after hand-searching the refer-
ence lists and another 4 by asking experts in the field. After
screening all titles and abstracts, 956 records were exclu-
ded (Fig. 1). Sixty-five full-text articles were assessed for
eligibility, of which 14 were selected. There were no arti-
cles excluded because of the administration time of the test.
In three articles, the sensitivity and specificity were
reported, but the exact numbers of evaluated patients were
lacking. After contacting the publication authors, we
retrieved the data for one of these papers. The other two
studies [10, 11] were excluded, as the requested data were
not available. One article reported on the aphasia item of
the Scandinavian Stroke Scale (SSS). This study did not
meet the inclusion criteria, since the SSS is a post hoc
scoring system and not a screening test. Eventually, we
included 11 articles, including 1 review [12]. In total, eight
screening tests for aphasia were evaluated.
Included studies
Table 1 shows the characteristics of the patient samples of
the ten included validation studies (the table does not
contain the review article [12]) ordered alphabetically by
screening test. One paper reported on the validation of two
screening tests [13], a full version and a short version of the
same test, and two tests were evaluated in more than one
study [13–18]. Sample sizes ranged from 37 [19] to 194
[16] patients. Only two studies provided details concerning
the type of stroke (i.e., ischemic versus hemorrhagic)
[18, 20]. In two papers, information on age and sex of the
patient sample was lacking [14, 15], and another three
evaluated a rather young cohort (i.e., mean age of 54
[13, 18] and 55 [17] years). In one study, the screening test
was validated in the chronic stage [17], and in three studies,
the time since stroke onset was not reported [13, 21, 22].
Screening tests included in the review
We included validation studies for nine screening tools: the
full and the short version of the Frenchay Aphasia
Screening Test (FAST) [13–15], Language Screening Test
(LAST) [21], Mississippi Aphasia Screening Test (MAST)
[16, 17, 23], the mobile aphasia screening test (also
abbreviated as MAST) [18], ScreeLing [20], Sheffield
Screening Test for Acquired Language Disorders (SST)
[13], Semantic Verbal Fluency (SVF) [22], and Ullevaal
Aphasia Screening test (UAS) [19]. Characteristics of the
screening tests, including language, subtests, score range,
administration time, type of patients, the test was originally
designed for, and applicability as a bedside screening tool
are given in Table 2. Two of the validation studies were
conducted in English, two were conducted in Korean, one
in Norwegian, one in French, one in Czech, one in Spanish,
and one in Dutch [13–15, 23, 24]. All tests can be
administered within 15 min and most of them are judged to
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be suitable for bedside use. The SVF [22] was originally
designed for patients with dementia [24]. The SST [13] and
the MAST [23] were not developed specifically for stroke
patients, but to assess language deficits in general. The
mobile aphasia screening test is a tablet application based
on the Korean version of the FAST and explicitly designed
with no tool requirements so to be used for patients in
remote locations easily [18].
Methodological quality of the validation studies
Table 3 provides information on methodological features
for each validation study, including reference test used, test
assessors and blinding of test assessors, and consecutive-
ness of patient inclusion. In more than half of the studies,
patients were not included consecutively
[13, 16–18, 21, 22]; and for one study, this information was
missing [14]. The diagnostic test that was applied as the
gold standard varied from an informal evaluation by an
SLT to extensive aphasia test batteries. In most studies, the
reference diagnosis was made by an SLT [13–16, 19]; in
two studies, this information was not reported [21, 22] or
not exactly specified [17]. The screening tests were carried
out by various disciplines. Most studies did not provide
information on the time interval between the assessment of
the reference test and the screening test [13–15, 20–22], as
was the case with respect to the order in which the
assessments were conducted [13, 14, 16, 17, 20, 22].
One study lacked blinding [17], in one study, blinding
was reported to be secured, but it was not specified how
[21], and seven studies did not describe whether or not test
assessors were blinded [13–16, 18, 22]. Three studies
reported on cut-off scores for the screening test indicating
the presence or the absence of aphasia, which were strati-
fied for age [13, 16, 18], and in one study, no cut-off score
was reported [19]. In three studies [13, 15, 16], the cut-off
value for the screening test was based on the previous
studies comparing subjects with aphasia and healthy con-
trol persons.
Table 4 shows the diagnostic properties of the identified
aphasia screening tests (sensitivity, specificity, LR?, LR-,
and DOR). In all studies, every patient was reported to be
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Table 1 Characteristics of the study cohorts of the validation studies
Study Screening test N Stroke typea (n/n) Age (year) (mean) Male sex n (%) Time since onset (days)
Al-Khawaja 1996 [13] FAST 50 n.r.b 54 32 (64) n.r.
Enderby 1987 [14] FAST 50 n.r. n.r. n.r. 1–36
O’Neill 1990 [15] FAST 54 n.r. n.r. n.r. 1
Flamand-Roze 2011 [21] LAST 102 n.r. 62 52 (51) n.r.
Choi 2015 [18] MAST* 60 41/19 54 47 (78) 2–8
Kostalova 2008 [16] MAST 194 n.r. 68–71c 97 (50) 1–46
Romero 2012 [17] MAST 58 10/19 55 32 (55) 277d
Doesborgh 2003 [20] ScreeLing 63 54/9 62 43 (68) 2–11
Al-Khawaja 1996 [13] SST 50 n.r.b 54 32 (64) n.r.
Kim 2011 [22] SVF 53 27/n.r. 66 36 (68) n.r.
Thommessen 1999 [19] UAS 37 n.r. 76 15 (41) 3–8
FAST Frenchay Aphasia Screening Test, LAST Language Screening Test, MAST* Mobile Aphasia Screening Test, MAST Mississippi Aphasia
Screening Test, SST Sheffield Screening Test for acquired language disorders, SVF semantic verbal fluency, UAS Ullevaal Aphasia Screening
Test, n.r. not reported
a n (ischemic stroke)/n (hemorrhagic stroke)
b 8 patients with traumatic brain injury were included in the study
c Median
d Mean
Table 2 Characteristics of the screening tests
Screening
test
Language in
which the
study was
conducted
Subtests Score
range
Administration
time
Designed for Bedside
FAST English Full form: comprehension; expression;
reading; writing
0–30
(full)
10 min Stroke Yes
Short form: comprehension; expression 0–20
(short)
3 min
LAST French Naming; repetition; automatic speech;
picture recognition; executing verbal
orders
0–15 2 min Stroke Yes
MAST* Korean Expression; comprehension 0–20 3 min Stroke n.r.
MAST Czech and
Spanish
Naming; automatic speech; repetition;
following instructions; yes/no responses;
writing/spelling; object recognition;
reading and executing instructions; verbal
fluency
0–100 5–10 min Severely impaired
language/communication
Yes
ScreeLing Dutch Semantics; phonology; syntax 0–72 15 min Stroke Yes
SST English Receptive skills; expressive skills 0–20 3–5 min Suspected language
disorders
Yes
SVF Korean Semantic fluency: animals n.a. i. 60 s Dementia n.r.
ii. 30 s
UAS Norwegian Expression; comprehension; repetition;
reading; word strings; writing; free
communication
n.r. 5–15 min Stroke n.r.
n.a. not applicable
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assessed with the reference test as well as with the
screening test. Four studies included a larger group of
patients with aphasia than without aphasia [13, 16, 21, 22],
and two included groups of equal sample size [17, 18]. In
five studies, the DOR was infinite, because either LR- was
nil or LR? was infinite [13, 14, 17, 21].
In Table 5, the estimated degree of bias is given based
on scores for blinding of test assessors, consecutiveness of
inclusion, and representativeness of the patient sample.
Seven studies were judged as having a high risk of bias,
two as having an intermediate risk of bias, and in one
study, the risk of bias was judged low. Four screening tools
seemed to perform very good (Table 4), with sensitivity
and specificity of 100 and 90 %, respectively (short version
of FAST [14]), 98 and 100 % (LAST [21]), 86 and 96 %
(ScreeLing [20]), and 90 and 100 % in one ([17]) and 96
and 89 % in another study [16] (MAST). However, the
validation studies for the FAST short version and both
validation studies for the MAST were considered as having
a high risk of bias. Of the three studies with an intermediate
or low risk of bias, the calculated DOR was highest for the
LAST [21] and Screeling [20].
Discussion
Given the impact of aphasia on the quality of life, reha-
bilitation after stroke, and the costs of stroke care [25], it is
of great importance that aphasia in stroke patients is
immediately recognized, allowing for adequate referral and
Table 3 Methodological features of the validation studies
Study Screening
test
Reference Assessor of
reference test
Assessor of screening test Cut-off for
screening test
Blindinga Consecutive
inclusion
Al-Khawaja
1996 [13]
FAST SLT SLT Non-specialist, n.f.s. 17b; 16c; 15d
(short)
n.r. No
Enderby 1987
[14]
FAST SLT, FCP,
sS
SLT n.r. 23 (full); 14
(short)
n.r. n.r.
O’Neill 1990
[15]
FAST sS, BDAE SLT Physician 25 n.r. Yes
Flamand-Roze
2011 [21]
LAST BDAE n.r SLT, nurse, neurologist,
or student
15 Yes,
n.f.s.
No
Choi 2015 [18] MAST* Physiatrist Physiatrist Research assistant, test
scored by SLT
16j; 14k n.r. No
Kostalova 2008
[16]
MAST SLT SLT Neurology resident and
student
93e; 96f; 98g n.r. No
Romero 2012
[17]
MAST BDAE, TT Clinical expert,
n.f.s.
Clinical expert, SLT,
neurologist
90 No No
Doesborgh 2003
[20]
ScreeLing TT, exp. Neurologist,
linguist
n.r. 66 Yes, 3 Yes
Al-Khawaja
1996 [13]
SST SLT SLT Non-specialist, n.f.s. 17h; 16i; 15d n.r. No
Kim 2011 [22] SVF STAND n.r. n.r. 60 s; 7/30 s; 6 n.r. No
Thommessen
1999 [19]
UAS SLT, parts of
NGA
SLT Nurse n.r. Yes, 2 Yes
SLT speech and language therapist, FCP functional communication profile, sS short Schuell, BDAE Boston Diagnostic Aphasia Examination, TT
Token Test, exp. expert assessment, NGA Norsk grunntest for afasi (Norwegian Basic Aphasia Assessment), TAND Screening Test for Aphasia
and Neurologic-Communication Disorders, n.f.s. not further specified, n.r. not reported
a Blinding: 1 for reference test only, 2 for screening test only, 3 for reference and screening test
b For age B59 years
c For age 60–70 years
d For age C71 years
e For age B60 years
f For age 61–70 years
g Basic and secondary education
h Academic education, age C60 years
i Academic education, age\60 years
j For age B64 years
k For age[64 years
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treatment as soon as possible. Hence, it is crucial to have a
brief and easy screening test for aphasia that may be
administered by SLTs as well as other health professionals
shortly after aphasia onset and is also suited for ill stroke
patients for whom an extensive test battery is too
demanding. A simple screening tool for aphasia may also
be of use for research purposes, to identify patients with
aphasia in stroke trials.
In this systematic review, we evaluated ten studies
reporting on the validation of eight screening tests for
aphasia after stroke, with emphasis on the methodological
quality of the validation study. Nearly, all included
screening tools usually reflect the approach taken in the
traditional aphasia test batteries that assess language
modalities, such as spontaneous speech, auditory and
written comprehension, reading and writing in addition to
naming and repetition, except the ScreeLing and the SVF.
The ScreeLing comprises tasks directly aimed at the basic
linguistic components (semantics, phonology, and syntax).
The SVF addresses semantic verbal fluency only. Although
it is not always explicitly mentioned in the test descrip-
tions, all tests are suitable to be administered at bedside, a
requirement for the use in the acute stage.
Several issues have to be taken into account when
appraising studies that claim to validate a screening test
against a reference test [8]. Clearly, the patient sample of
the validation study should be representative for the pop-
ulation in which the screening test will be applied. This
means that a screening tool for aphasia due to stroke should
be verified in a cohort representative for the general stroke
population. For this reason, we only included validation
studies performed on stroke patients with and without
aphasia, and excluded studies investigating test perfor-
mance by examining aphasic stroke patients and healthy
controls. We attempted to assign a score for representa-
tiveness to each included study based on the available
information on patient characteristics. Unfortunately, data
on age and sex of the patient sample were not reported for
all studies. Furthermore, in more than half of the validation
studies, patients were not included consecutively, or this
information was missing. Consecutive inclusion increases
the likelihood that the full spectrum of aphasia severity is
represented in the study cohort and minimizes the risk of
selection bias. The 1:1 ratio of patients with and without
aphasia in some of the validation studies [17, 18, 22],
however, suggests that the patients were not recruited
consecutively but rather selected. One study that reported
consecutive inclusion only enrolled patients already sus-
pected to have aphasia, resulting in a study cohort con-
taining a majority (i.e., 90 %) of stroke patients with
aphasia [13]. In all the studies, the number of non-verified
patients was nil, which indicates that selection bias may
have been present to some extent. It is possible that only
patients who were able to undergo the screening test as
well as the reference test were enrolled, while patients for
whom the burden of the reference test (which is likely to be
more time-consuming and more difficult) was too high
were not included. In addition, the administration of the
reference test should not be restricted to patients in whom
the screening test was positive, to avoid workup bias. In
Table 5 Risk of bias in evaluated validation studies
Study Screening test Score for blindinga Score for consecutivenessb Score for representativenessc Risk of biasd
Al-Khawaja 1996 [13] FAST 0 0 1 High
Enderby 1987 [14] FAST 0 0 0 High
O’Neill 1990 [15] FAST 0 2 0 High
Flamand-Roze 2011 [21] LAST 1 0 2 Intermediate
Choi 2015 [18] MAST* 0 0 2 High
Kostalova 2008 [16] MAST 0 0 2 High
Romero 2012 [17] MAST 0 0 1 High
Doesborgh 2003 [20] ScreeLing 2 2 2 Low
Al-Khawaja 1996 [13] SST 0 0 1 High
Kim 2011 [22] SVF 0 0 2 High
Thommessen 1999 [19] UAS 1 2 1 Intermediate
a 0: assessment was not blinded or blinding was not reported on, 1: blinding for the screening test only, or blinding without further specification,
2: blinding for both the reference and the screening test
b 0: no consecutive inclusion or consecutiveness not reported, 2: consecutive inclusion of patients
c Based on the size of the cohort, available data on stroke type, and mean age and sex of the study population, 0: not representative or not
reported, 1: fairly representative or partially not reported, 2: very representative
d Total score B2: high, total score C3 and B4: intermediate, total score C5: low
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each study included in this review, all patients were
reported to be assessed both with the screening test and the
test used as the gold standard.
For many of the screening tools, the cut-off value below
or above which the test result is considered abnormal (i.e.,
the patient is diagnosed as having aphasia) was derived
from studies performed in stroke patients with aphasia and
healthy control subjects, while cut-off values based on a
general stroke population are preferred. Finally, the
assessor of the screening test should be blind for the result
of the reference test and the other way around. Many of the
evaluated studies did not report whether or not blinding
was secured, making it difficult to estimate the risk of
expectation bias. Altogether, most of the validation studies
had serious methodological limitations, thus hampering
firm conclusions about utility of the aphasia screening tools
for clinical practice.
Of the four studies with an intermediate or low risk of
bias, the LAST [21] and Screeling [20] seem to have the
best diagnostic properties. An advantage of the LAST is
the short administration time. The ScreeLing, a measure
for the patients’ functioning in the main linguistic levels
semantics, phonology, and syntax, gives more detailed
information for language treatment. It is notable that the
SVF, a very short screening test that was initially devel-
oped for use in patients with dementia, also performs
quite reasonably as a screening test for aphasia in stroke
patients [22].
Besides the screening tools evaluated in this review,
there are several well-known screening tests for aphasia
that are widely used in clinical practice. For the Acute
Aphasia Screening Protocol [26], the Aachen Aphasia
Bedside Test [27], and the Bedside Western Aphasia Bat-
tery [28], strikingly, we were unable to find any peer-re-
viewed articles in which these tests were validated in stroke
patients with and without aphasia. The Token Test [29] is
one of the first recommended screening tests for the
detection of aphasia in patients with neurological damage
and, therefore, exists in a lot of variants [30–32]. However,
although this test is generally considered very useful in
clinical practice, it could not be included, because the
etiology of aphasia was too diverse or unspecified in the
validation studies for this test. Finally, general stroke scales
quantifying stroke severity in the acute stage contain
specific subparts for speech and language, such as the NIH
Stroke Scale (NIHSS) [33], the Canadian Neurological
Scale (CNS) [34], and the European Stroke Scale (ESS)
[35]. These standardized scales are often used in clinical
practice to identify stroke patients with aphasia, but have
not been systematically validated as such.
In conclusion, several screening tools for aphasia in
stroke are available, but many tests have not been verified
in a proper way. Future studies should focus on a better
validation of the available aphasia screening tests in large
stroke populations. The design should include a reliable
reference diagnosis, a consecutive inclusion of stroke
patients to make them representative of a general stroke
population, a secured blinding of the assessments, details
on the numbers of aphasics and non-aphasics correctly
classified, and a good description of the subtests of the
screening test, to eliminate the risk of bias as much as
possible.
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